Abbott Inks $670M Deal To End Some Preterm Formula Claims
Abbott Laboratories announced Thursday that it has agreed to pay about $670 million to partially resolve ongoing litigation alleging its specialty baby formula caused premature babies to suffer a disabling intestinal...To view the full article, register now.
Already a subscriber? Click here to view full article